Clinical Trial Update: Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating left ventricular hypertrophy and spironolactone in chronic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Failure Chronic

Drugs mentioned

• Spironolactone (spironolactone)

Snippet

Sponsor: Dawnmarie DeFazio | Conditions: Kidney Failure, Chronic | Phase 4 | Status: WITHDRAWN